Information  X 
Enter a valid email address

Alliance Pharma PLC (APH)

  Print      Mail a friend       Annual reports

Tuesday 26 February, 2019

Alliance Pharma PLC

Notification of Preliminary Results

RNS Number : 0672R
Alliance Pharma PLC
26 February 2019
 

 


                                             26 February 2019

 

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Notification of Preliminary Results

 

Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its preliminary results for the year ended 31 December 2018 on Tuesday 26 March 2019.

 

A briefing for analysts will be held at 11.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

 

To access a webcast of the analyst presentation, please log on to the following web address several minutes before 11.00am on the day of the results:

 

http://webcasting.buchanan.uk.com/broadcast/5c6e8e68e6e1d92d38f4f7e1

 

For more information, please contact Buchanan on 020 7466 5000 or email [email protected].

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer


Andrew Franklin, Chief Financial Officer


www.alliancepharma.co.uk


Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff




Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield


Corporate Broking: James Black


 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas


Corporate Broking: Patrick Robb / Tejas Padalkar


 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with affiliate offices in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We currently own or license the rights to more than 90 pharmaceutical and consumer healthcare products, which are managed on a portfolio basis according to their growth potential. Promotional investment is focussed on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our tried and tested 'Buy and Build' strategy, allows us to benefit both from organic growth opportunities and from enhancing our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com  

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORDELFLKLFEBBB

a d v e r t i s e m e n t